A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

NCT00811018 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
1192
Enrollment
INDUSTRY
Sponsor class

Stopped This trial was prematurely terminated on Dec 9 2010 due to safety concerns, specifically emerging evidence of hepatic injury.

Conditions

Interventions

Sponsor

Pfizer